United Therapeutics Q4 2024 revenue rises 20% to $735.9 million; net income up
United Therapeutics reported fourth quarter and full year 2024 results on February 26, 2025. Revenue for the quarter rose 20% to $735.9 million and net income rose to $301.3 million, while full year revenue reached a record $2.88 billion, up 24%. Higher earnings for both periods point to strong sales of its treprostinil products for shareholders, though the company also booked a $71.1 million litigation accrual tied to Sandoz Inc. for 2024.
Key points
- Q4 2024 diluted EPS was $6.19, compared with $4.36 in Q4 2023.
- Full year 2024 net income was $1,195.1 million, compared with $984.8 million in 2023.
- Total Tyvaso revenue grew 19% to $415.9 million in Q4 2024.
- A $71.1 million accrual related to ongoing litigation with Sandoz Inc. was recorded as of December 31, 2024.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.